Scinai Immunotherapeutics (NASDAQ:SCNI) is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immunotherapies for the treatment of cancer. Publicly traded on the NASDAQ under the ticker SCNI, Scinai leverages proprietary technologies to stimulate and direct T-cell responses against tumor cells. The company’s research efforts are centered on enhancing the body’s natural immune defenses through synthetic agonists and targeted adjuvant systems designed to optimize antigen presentation and immune activation.
The core of Scinai’s platform is its Stimulator of Nuclear Receptor (SNR) technology, which consists of small‐molecule modulators and peptide conjugates engineered to engage key immune checkpoints and intracellular signaling pathways. This approach underpins the company’s lead candidates, which are currently advancing through preclinical validation and early-stage clinical trials. In parallel, Scinai is exploring combination strategies that pair its immunomodulatory agents with established chemotherapy and radiotherapy regimens to maximize anti-tumor efficacy.
Founded in 2018 and headquartered in New York, Scinai operates research laboratories and satellite offices in both the United States and Europe. The company has established collaborations with leading academic research centers, contract research organizations, and strategic partners to accelerate its pipeline development. By leveraging these alliances, Scinai aims to streamline translational research efforts, from biomarker discovery to clinical proof-of-concept studies, in multiple oncology indications including solid tumors and hematologic malignancies.
Scinai is led by a management team and board of directors with extensive backgrounds in oncology drug development, regulatory affairs, and commercial strategy. The executive leadership has held senior roles at major pharmaceutical firms and biotech startups, providing depth in clinical operations, manufacturing scale-up, and global market access. Together, they are committed to advancing Scinai’s immunotherapy portfolio toward proof of safety and efficacy in cancer patients worldwide.
